Original Research

Published on 24 Sep 2024

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b

in Pharmacology of Anti-Cancer Drugs

Albert Qin
Daoxiang Wu
Jason Liao
Shuping Xie
Haoqi Chen
Yucheng Gao
Jie Cui
Xia Su
Narihisa Miyachi
Toshiaki Sato

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1455979

210 views

Original Research

Accepted on 23 Sep 2024

KHSRP knockdown inhibits papillary renal cell carcinoma progression and sensitizes to gemcitabine

in Pharmacology of Anti-Cancer Drugs

Wei Song
Heng Zhang
Yi Lu
Houliang Zhang
Jinliang Ni
Lan Chang
Yongzhe Gu
Guangchun Wang
Tianyuan Xu
Zonglin Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1446920

Original Research

Accepted on 23 Sep 2024

Targeting Autophagy: Polydatin's Role in Inducing Cell Death in AML

in Pharmacology of Anti-Cancer Drugs

Ping Fu
Qing Luo
Chao Wang
Liping Chen
Chang Dong
Ke Yang
Guang Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1470217

Original Research

Published on 23 Sep 2024

Analysis of chromatin accessibility in peripheral blood mononuclear cells from patients with early-stage breast cancer

in Pharmacology of Anti-Cancer Drugs

Longjie Xia
Jiamin Lu
Yixuan Qin
Runchun Huang
Fanbiao Kong
Yu Deng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1465586

139 views

Review

Published on 20 Sep 2024

Advancing cancer therapy: new frontiers in targeting DNA damage response

in Pharmacology of Anti-Cancer Drugs

Jiekun Qian
Guoliang Liao
Maohui Chen
Ren-Wang Peng
Xin Yan
Jianting Du
Renjie Huang
Maojie Pan
Yuxing Lin
Xian Gong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1474337

185 views

Original Research

Published on 20 Sep 2024

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

in Pharmacology of Anti-Cancer Drugs

Qiong Jie
Yuanyuan Li
Li Jing
Jinjin Chen
Yang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1424980

125 views

Original Research

Accepted on 18 Sep 2024

DNA Methylation Inhibitors Adverse Reaction Characteristic Analysis: A Descriptive Analysis from WHO-VigiAccess

in Pharmacology of Anti-Cancer Drugs

Zhou Qiang
Xie Quanlei
Liu Qiang
Wang Haojie
Zhang zhan
Zhao Yu
Qian Guo
Jie Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1470148

Mini Review

Accepted on 18 Sep 2024

Assessment of Ferroptosis as a Promising Candidate for Metastatic Uveal Melanoma Treatment and Prognosis

in Pharmacology of Anti-Cancer Drugs

Ellie Swords
Breandán Kennedy
Valentina Tonelotto

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1466896

Systematic Review

Published on 18 Sep 2024

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials

in Pharmacology of Anti-Cancer Drugs

Guojuan Sun
Yi Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1460285

112 views

Review

Accepted on 17 Sep 2024

RGD-Based Self-Assembling Nanodrugs for Improved Tumor Therapy

in Pharmacology of Anti-Cancer Drugs

Hongfei Jiang
Bin Wang
Dongmei Tang
Jianqiao Cui
Jing Yu
Zhu Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1477409

Original Research

Published on 17 Sep 2024

Extrachromosomal circular DNAs in prostate adenocarcinoma: global characterizations and a novel prediction model

in Pharmacology of Anti-Cancer Drugs

Qingliu He
Qingfu Su
Chengcheng Wei
Pu Zhang
Weihui Liu
Junyi Chen
Xiaoping Su
Wei Zhuang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1464145

132 views

Original Research

Accepted on 16 Sep 2024

Dehydroepiandrosterone suppresses human colorectal cancer progression through ER stress-mediated autophagy and apoptosis in a p53-independent manner

in Pharmacology of Anti-Cancer Drugs

Thi-Huong Nguyen
Huey-Jiun Ko
Po-Yu Tsai
Tai-Shan Cheng
Peter Mu-Hsin Chang
Hsiao-Sheng Liu
Yi-Ren Hong
Chi-Ying Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1464647

Review

Accepted on 16 Sep 2024

Cell Cycle Checkpoint Revolution: Targeted Therapies in the Fight Against Malignant Tumors

in Pharmacology of Anti-Cancer Drugs

Guangming Song
Jue Liu
Xing Tang
Jie Zhong
Yuhuan Zeng
Xiaodi Zhang
Jianbin Zhou
Jie Zhou
Lu Cao
Qunfeng Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1459057

Review

Accepted on 16 Sep 2024

Diversified Applications of Hepatocellular Carcinoma Medications: Moleculartargeted, Immunotherapeutic, and Combined Approaches

in Pharmacology of Anti-Cancer Drugs

Haoyang Chen
Huihui Liu
Xiaowei Zhang
Suhua Wang
Chunxia Liu
Ke An
Ruijuan Liu
Xin Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1422033

Original Research

Published on 16 Sep 2024

Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Yaojun Peng
Lingxiong Wang
Juan Yang
Qiyan Wu
Xiaoxuan Sun
Jinying Zhang
Yanju Yu
Liping Zhang
Jie Gao
Qing Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1466779

193 views

Opinion

Published on 16 Sep 2024

Cholesterol metabolism: a positive target to revoke the function of exhausted CAR-NK cells in tumor microenvironment

in Pharmacology of Anti-Cancer Drugs

Jingfeng Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1440869

137 views

Navigation group

Articles

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b

KHSRP knockdown inhibits papillary renal cell carcinoma progression and sensitizes to gemcitabine

Targeting Autophagy: Polydatin's Role in Inducing Cell Death in AML

Analysis of chromatin accessibility in peripheral blood mononuclear cells from patients with early-stage breast cancer

Advancing cancer therapy: new frontiers in targeting DNA damage response

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system

DNA Methylation Inhibitors Adverse Reaction Characteristic Analysis: A Descriptive Analysis from WHO-VigiAccess

Assessment of Ferroptosis as a Promising Candidate for Metastatic Uveal Melanoma Treatment and Prognosis

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials

RGD-Based Self-Assembling Nanodrugs for Improved Tumor Therapy

Extrachromosomal circular DNAs in prostate adenocarcinoma: global characterizations and a novel prediction model

Dehydroepiandrosterone suppresses human colorectal cancer progression through ER stress-mediated autophagy and apoptosis in a p53-independent manner

Cell Cycle Checkpoint Revolution: Targeted Therapies in the Fight Against Malignant Tumors

Diversified Applications of Hepatocellular Carcinoma Medications: Moleculartargeted, Immunotherapeutic, and Combined Approaches

Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma

Cholesterol metabolism: a positive target to revoke the function of exhausted CAR-NK cells in tumor microenvironment